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DRUG-RELATED MORBIDITY AND MORTALITY

Drug-Related Morbidity and Mortality
in Maine:
Lost Productivity from 2015 to 2020
by Angela Daley, Prianka Maria Sarker, Liam Sigaud, Marcella H. Sorg, and Jamie A. Wren

Drug misuse and overdose deaths
have far-reaching consequences for the
In this article, we characterize drug-related morbidity and mortality in Maine
individuals and their families and
between 2015 and 2020, as well as the impact on labor market and nonmarcommunities, including poor physical
ket productivity. We find that prevalence of drug misuse and the number of
and mental health, reduced quality of
drug-related deaths have increased across time, and both are lower among
life, lost productivity, increased accidents
females vs males. Drug-related morbidity is concentrated among individuand crime, and higher social welfare and
als aged 18–25, while mortality is concentrated among those aged 25–54.
health care costs ( US DHHS 2016  ).
Lost productivity has increased across time and is lower among females vs
Florence et al. ( 2021 ) estimated the
males. In 2019, lost productivity was $271 million (annual) from morbidity and
economic impact of these consequences
$565 million (lifetime) from mortality. These estimates reflect the lost value to
to be $1,021 billion in 2017, or $3,140
Maine that occurs when individuals cannot fully contribute to the labor marper person in the United States.2 The
ket or nonmarket activities. On balance, our study provides important informost recent Maine-based study was
mation about the drug epidemic in Maine, which may be helpful to decision
conducted by Rogers et al. ( 2013 ),
makers as they design and evaluate relevant policies and programs.
before the surge in drug misuse and overdose deaths due to fentanyl, using 2010
data. According to their study, which
INTRODUCTION
considered both alcohol and drugs, the impact was estimated to be $1.4 billion, or $1,057 per person in Maine.
rug misuse and overdose deaths are a critical public
A more recent study by Luo et al. ( 2021 ), which used
health challenge in the United States. More than
national cost estimates and state-level case counts, esti70,000 Americans died from a drug-involved overdose
mated the impact of the opioid epidemic in Maine to be
in 2019 alone—a number that has increased four-fold
$6.8 billion in 2017. This amounts to $5,099 per Mainer,
since 1999. This increase was initially driven by deaths
the sixth highest per capita cost in the nation. In the study
involving pharmaceutical opioids, followed by an increase
by Luo et al. ( 2021 ), a large share of the cost was attribin heroin involvement as of 2010. Starting in 2013, there
utable to reduced quality of life from opioid use disorder
was an increase in deaths caused by nonpharmaceutical
and the value of life lost due to overdose deaths, followed
synthetic opioids, particularly fentanyl and its analogs.
by lost productivity. Lost productivity reflects the negative
Mirroring the national crisis, Maine has experienced a
impact on society when individuals cannot fully contribute
substantial increase in overdose deaths since 1997 (Sorg
to the labor market and to nonmarket activities such as
and Greenwald 2003; Sorg et al. 2016). For example,
household work, care giving, and volunteering.
the number of overdose deaths in Maine increased by
In this article, we provide a current Maine-based
33 percent between 2019 and 2020 (from 380 to 504
analysis
of drug-related morbidity ( ill health ) and
deaths), and most of these deaths were caused by opioids
mortality. Specifically, we examine the prevalence of drug
combined with other drugs or alcohol (Sorg 2021). The
misuse, the number of drug-related deaths, and years of
per capita overdose death rate in Maine has ranked among
1
potential life lost, as well as the impact on market and
the highest in the nation for the last several years.
Abstract

D
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nonmarket productivity. Our study spans the years 2015
to 2019, as well as 2020 for drug-related mortality. This
period was characterized by a surge in drug misuse and
overdose deaths in Maine ( Sorg 2021 ). We present estimates across time, rather than in a single-year snapshot or
aggregate of multiple years. We further differentiate by sex
and age group to provide insight into the distributional
effects of the drug epidemic.
Our goal with this study is to assist decision makers
by characterizing the drug epidemic in Maine and
measuring the impact on productivity—information that
is important when targeting and evaluating interventions.
It should be reiterated that, other than reduced quality of
life and the value of life lost ( both of which are difficult to
measure ), lost productivity is the largest economic cost of
drug-related morbidity and mortality ( Florence et al.
2021; Luo et al. 2021; Rogers et al. 2013 ). We recognize,
however, that it co-occurs with other substantial costs,
including those related to accidents and crime, social
welfare programs, and health care, in addition to the
far-reaching emotional toll ( Verhaeghe et al. 2017 ).
DATA AND METHODOLOGY

In general, we use a human capital approach to estimate lost productivity from drug-related morbidity and
mortality in Maine. This approach, which has been widely
used in previous studies, measures the lost value to society
that occurs when individuals cannot fully contribute to
market and nonmarket activities ( Goodchild et al. 2018;
Verhaeghe et al. 2017 ). For example, individuals may be
less likely to participate in the labor market, or they may
be less productive due to absenteeism, problems with
concentration and memory, impaired judgment, or interpersonal challenges.3 This loss of productivity negatively
affects their earnings, as well as the productivity of their
employers and the economy as a whole. Of course,
drug-related morbidity and mortality also affect nonmarket
activities, such as household work, care giving, and volunteering. The effect on nonmarket activities should be
considered when estimating the lost value to society,
otherwise the analysis will not accurately reflect the contributions of children, students, retirees, and others who are
less likely to be in the labor market.
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Morbidity

Before estimating lost productivity from drug-related
morbidity, we consider the prevalence of illicit drug use
disorder ( IDUD ), which is defined by the National
Survey on Drug Use and Health as dependence on, or
misuse of, prescription psychotherapeutics, marijuana,
cocaine, crack, heroin, hallucinogens, inhalants, or methamphetamine. The prevalence data span the years 2015–
2016 to 2018–2019 and are given by age group ( 12–17,
18–25, 26+ ) with 95 percent confidence intervals
( SAMHSA 2017a; 2018a; 2019a; 2020a ). These data are
not available by sex at the state level, so we calculate
sex-specific prevalence using the proportion of IDUD
cases in the United States that are female and male, respectively ( SAMHSA 2017b; 2018b; 2019b; 2020b ) and
state population estimates from the US Census Bureau.4

Our goal with this study is to assist
decision makers by characterizing the
drug epidemic in Maine and measuring
the impact on productivity
After characterizing drug-related morbidity in Maine,
we estimate the economic impact using data on annual
market, nonmarket, and total productivity per person in
the United States, disaggregated by sex and age group
( Grosse et al. 2019 ). Coinciding with these data, the US
Department of Justice finds that drug misuse reduces
productivity by 18 percent among females and 17 percent
among males ( NDIC 2011 ). Thus, similar to past studies,
we use this information to calculate the annual lost
productivity per person ( Florence et al. 2021; McDowell
Group 2020 ). We adjust the estimates to 2019 dollars
using the annual average consumer price index ( CPI-U )
from the US Bureau of Labor Statistics. Also, following
Rogers et al. ( 2013 ), we multiply the estimates by 0.9216
to reflect differences in median household income between
Maine and the United States during our study period.
Finally, to aggregate estimates to the state level, we
multiply the annual lost productivity per person by the
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number of IDUD cases for each sex and
age group. When calculating lost market
productivity, we further multiply by
0.6097 to account for the fact that only
60.97 percent of the Maine population
had labor market productivity during our
study period.5

figure 1:

Prevalence of Illicit Drug Use Disorder by Sex and Overall
from 2015–2016 to 2018–2019

7%

Female

Male

Overall

6%
5%

Mortality
4%
Before estimating lost productivity
3%
from drug-related mortality, we consider
the number of deaths and years of poten2%
tial life lost. Our data include accidental,
suicidal, and undetermined causes of
1%
death that were directly or partially attrib0%
utable to drugs, as determined by the
2015–2016
2016–2017
2017–2018
2018–2019
medical examiner ( Sorg 2021 ). The data
were extracted locally from the medical
Note: The bars show 95 percent confidence intervals.
examiner’s records, prior to analysis by the
National Center for Health Statistics,
data to 2019 dollars using the annual average CPI-U, and
which sorts vital records by state according to residency.
we multiply by 0.9216 to reflect differences in median
Therefore, our data include all drug-related deaths that
household income between Maine and the United States.
occurred in Maine regardless of whether they were resiFinally, to calculate lifetime lost productivity at the state
dents. As such, the data reflect occurrent deaths rather
level, we multiply the per person estimates by the number
than resident deaths. They are given by sex and age group
of drug-related deaths for each sex and age group.7
( 0–18, 19–24, 25–34, 35–44, 45–54, 55–64, 65+ ) from
2015 to 2020. We present the number of drug-related
RESULTS
deaths as a crude rate per 100,000 population. Moreover,
to calculate the years of potential life lost, we multiply the
Morbidity
number of deaths in each sex and age group by the corres can be seen in Figure 1, drug-related morbidity is
sponding average life expectancy, weighted by the age
consistently lower among females compared to males,
6
distribution of the population.
although
it increased across time for both.8 In 2018–2019,
After describing drug-related mortality in Maine, we
the prevalence of IDUD was 2.8 percent among females
consider the economic impact using data on lifetime
and 4.5 percent among males. It was 3.6 percent overall
productivity per person in the United States, disaggre(the 95 percent confidence interval ranges from 2.7 to 4.9
gated by sex and age ( Grosse et al. 2019 ). In the data,
percent).
lifetime productivity is discounted at a rate of 3 percent
Disaggregating by age group, Figure 2 shows that
per year, which is consistent with recent literature ( Florence
drug-related morbidity is considerably higher among indiet al. 2021 ) and recommended in the United States
viduals aged 18–25, regardless of sex. We also find that
( Sanders et al. 2016 ). However, as lower bound estimates,
upward trends in drug-related morbidity are driven by this
we also consider a version of the data in which lifetime
age group. During our study period, the prevalence of
productivity is discounted at a rate of 7 percent per year.
IDUD increased from 5.6 to 8.2 percent among females
Likewise, the data account for a productivity growth rate
aged 18–25, and from 9.0 to 11.2 percent among males
of 0.5 percent per year. They are also available with a 1
aged 18–25. It is also interesting to note that sex differpercent growth rate, which we consider as upper bound
ences are more pronounced in this age group, while the
estimates. Similar to our morbidity estimates, we adjust all

A
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figure 2:

Prevalence of Illicit Drug Use Disorder by Sex and Age Group
from 2015–2016 to 2018–2019
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Note: 95 percent confidence intervals are available upon request.

figure 3:

Annual Lost Productivity Due to Drug-Related Morbidity
by Sex and Overall from 2015–2016 to 2018–2019

400
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Note: Annual lost productivity includes both market and nonmarket activities. The bars
show 95 percent confidence intervals.
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prevalence of IDUD is similar among
females and males aged 12–17.
Figure 3 depicts the impact of
drug-related morbidity on annual productivity, considering both market and
nonmarket activities. We find that lost
productivity is consistently lower among
females compared to males, although it
increased across time for both.9 In 2018–
2019, lost productivity was approximately
$102 million among females and $169
among males. It was approximately $271
million overall ( the 95 percent confidence
interval ranges from $198 million to $369
million ). This reflects the annual lost value
to Maine when individuals cannot fully
contribute to market and nonmarket
activities due to drug-related morbidity.
In Table 1, we further differentiate
between market, nonmarket, and total
productivity and we provide estimates by
sex and age group. In 2018–2019, lost
productivity among females was approximately $40 million in market activities
and $62 million in nonmarket activities.
Among males, it was $105 million in
market activities and $64 million in
nonmarket activities. Thus, in Maine
overall, annual lost productivity was $145
million in market activities ( i.e., individuals with drug-related morbidity were less
likely to participate in the labor market or
were less productive ) and $126 million in
nonmarket activities, such as household
work, care giving, and volunteering. We
also find that lost productivity is largely
attributable to individuals aged 26+. This
finding is expected because, even though
they have a relatively low prevalence of
drug-related morbidity, these individuals
are in their most productive years. Our
data are not available for more granular
age groups among individuals aged 26+.
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table 1:

Annual Lost Productivity (2019 $) Due to Drug-Related Morbidity by Sex and Age Group
from 2015–2016 to 2018–2019
Female
2015–2016

2016–2017

Male

2017–2018

2018–2019

2015–2016

2016–2017

2017–2018

2018–2019

Market
Age 12–17

1,532,359

Age 18–25

1,544,849

1,522,661

1,676,085

1,841,669

1,825,231

1,756,336

1,881,311

3,339,087

3,586,844

4,513,212

4,771,987

6,597,561

7,086,881

8,432,494

7,927,423

21,550,501

26,239,426

30,435,371

33,425,836

68,143,622

77,876,029

91,904,863

94,674,553

26,421,947

31,371,120

36,471,244

39,873,908

76,582,853

86,788,141

102,093,693

104,483,288

Age 12–17

3,494,181

3,522,662

3,472,069

3,821,914

2,171,940

2,152,554

2,071,304

2,218,692

Age 18–25

7,613,998

8,178,950

10,291,312

10,881,387

7,780,717

8,357,789

9,944,714

9,349,067

Age 26+
Total
Nonmarket

Age 26+

30,381,861

36,992,300

42,907,735

47,123,688

38,028,526

43,459,834

51,288,826

52,834,492

Total

41,490,040

48,693,911

56,671,116

61,826,989

47,981,183

53,970,178

63,304,845

64,402,251

Age 12–17

5,026,540

5,067,511

4,994,730

5,497,999

4,013,610

3,977,785

3,827,641

4,100,003

Age 18–25

10,953,085

11,765,794

14,804,524

15,653,374

14,378,278

15,444,671

18,377,208

17,276,490

Age 26+

51,932,362

63,231,726

73,343,106

80,549,524

106,172,148

121,335,863

143,193,689

147,509,045

67,911,987

80,065,031

93,142,360

101,700,897

124,564,036

140,758,319

165,398,538

168,885,538

Total

Total

Note: 95 percent confidence intervals are available upon request.

Figure 4:

Number of Drug-Related Deaths per 100,000 Population by
Sex and Overall from 2015 to 2020
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Mortality
Figure 4 shows that drug-related
mortality is lower among females vs males,
but it follows an upward trend for both.
During our study period, the number of
deaths increased by 62.7 percent among
females ( from 6.7 to 10.9 deaths per
100,000 population ) and 91.3 percent
among males ( from 13.8 to 26.4 deaths
per 100,000 population ). There was a
notable decline in drug-related mortality
among males in 2018 and an increase in
2020, which coincides with the
COVID-19 pandemic. In 2020, drug-related mortality in Maine was 37.3 deaths
per 100,000 population.
In Figure 5, we further differentiate
by age group. We find that drug-related
deaths are concentrated among individuals aged 25–64 vs individuals aged 0–24
or 65+.
MAINE POLICY REVIEW • Vol. 31, No. 1 • 2022
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figure 5:

Age Distribution of Drug-Related Deaths per 100,000 Population by Sex from 2015 to 2020
Age groups
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figure 6:
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Years of Potential Life Lost from Drug-Related Deaths by Age Group and Sex from 2015 to 2020
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Figure 6 shows that females lost fewer years of potential life from drug-related deaths than males did. Moreover,
there was a notable decline in 2018, especially for males,
followed by an increase during the COVID-19 pandemic.
In 2020, there were 18,634 years of potential life lost from
drug-related deaths in Maine ( 5,535 among females and
13,099 among males ). These years of potential life lost
were concentrated among individuals aged 25–54, who
represent a large share of drug-related deaths and would
otherwise have considerable life expectancy.
Figure 7 depicts the impact of drug-related mortality
on market and nonmarket productivity. We find that lost
productivity is considerably lower among females vs males

MAINE POLICY REVIEW • Vol. 31, No. 1 • 2022

2015

2016

2017

2018

2019

2020

in all years. In Maine overall, lost productivity has
increased across time, except in 2018, which corresponds
to the reduction in drug-related mortality among males.
In 2020, lifetime lost productivity was approximately
$734 million; by varying the discount and growth rates,
the lower and upper bounds are $475 million and $786
million, respectively. These estimates represent the lost
value to Maine in terms of market and nonmarket activities, not just in 2020, but over what would have been the
remaining lifetimes of those who died that year.
As can be seen in Table 2, lifetime lost productivity in
Maine is largely attributable to individuals aged 25–54.
For example, they accounted for more than 80 percent of
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figure 7:

Lifetime Lost Productivity Due to Drug-Related Mortality
by Sex and Overall from 2015 to 2020

Millions of 2019 $

has increased across time for both
females and males, and it was consistently lower among females. In 2019,
lost productivity was $271 million
Female
Male
Overall
( annual ) from morbidity and $565
800
million ( lifetime ) from mortality,
700
reflecting the lost value to Maine as
individuals could not fully contribute
600
to the labor market and nonmarket
500
activities. This total of $836 million is
400
considerably higher than lost productivity in 2010 and 2017 ( Rogers et al.
300
2013; Luo et al. 2021 ). However, we
200
urge caution when comparing these
100
estimates because data and methodology have evolved since Rogers et al.,
0
and Luo et al. focus exclusively on
2015
2016
2017
2018
2019
2020
opioids. We also remind readers that
our study emphasizes lost producNote: Lifetime lost productivity includes both market and nonmarket activities. Productivity data
tivity; we do not consider other relefrom Grosse et al. (2019) are based on a 3 percent discount rate and 0.5 percent growth rate. In
this figure, the bars show how the results change when these parameters are varied. The lower
vant costs, such as reduced quality of
bound estimates are based on a 7 percent discount rate and 0.5 percent growth rate. The upper
life or the value of life lost due to
bound estimates are based on a 3 percent discount rate and 1 percent growth rate.
overdose deaths. Considering a wide
array of costs, Luo et al. find that the
lost productivity in 2020 ( $605 million of $734 million ).
impact of the opioid epidemic in Maine was approxiThis is due to the age distribution of drug-related deaths
mately $6.8 billion in 2017. So, our lost productivity
( Figure 5 ) and because they are individuals in their most
estimates are just a fraction of the overall impact.
productive years.
Several limitations should be noted. First, we do not
have
data on the prevalence of IDUD in 2019–2020.
CONCLUSION
Moreover, by focusing on prevalence in a given period, we
do not capture the impact of drug-related morbidity over
n this article, we provide an up-to-date analysis of
an individual’s lifetime, although we recognize that lost
drug-related morbidity and mortality in Maine, along
productivity may begin to accumulate before diagnosis
with the impact on productivity. Our study covers the
and perpetuate after recovery. Finally, we do not consider
period from 2015 to 2020, when there was a surge in
the impact of drug-related incarceration on productivity,
drug misuse and overdose deaths (Sorg 2021). Indeed,
nor do we consider lost productivity among individuals
we find that prevalence of illicit drug use has increased
who
care for those who misuse drugs ( Reinhart et al.
over time, and it was consistently lower among females
2018 ).
compared to males. The number of drug-related deaths
As we stated earlier, our goal is to assist decision
followed a similar pattern, except there was a reduction
makers by characterizing drug-related morbidity and
among males in 2018, followed by a large increase in
mortality in Maine, and the impact on productivity, to
2020, the first year of the COVID-19 pandemic. It is also
help policymakers target and evaluate relevant policies
interesting that the increase in drug-related morbidity is
and programs. Future work should incorporate other
driven by individuals aged 18–25, while the increase in
costs ( e.g., reduced quality of life, the value of life lost,
mortality is driven by those aged 25–54.
accidents and crime, social welfare programs, health care )
In terms of economic impact, we find that lost
and continue to consider differences by sex and age.
productivity from drug-related morbidity and mortality

I
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Lifetime Lost Productivity (2019 $) Due to Drug-Related Mortality by Sex and Overall
from 2015 to 2020

table 2:

2015

2016

2017

2018

2019

2020

Female
Age 0–18

1,396,479

1,396,479

2,792,957

2,792,957

1,396,479

1,396,479

Age 19–24

8,911,435

19,605,157

7,129,148

7,129,148

8,911,435

10,693,722

Age 25–34

29,897,032

51,000,820

58,035,416

38,690,277

58,035,416

40,448,926

Age 35–44

25,997,881

49,107,109

27,442,208

34,663,842

43,329,802

63,550,377

Age 45–54

26,463,558

25,445,729

35,624,020

28,499,216

29,517,045

32,570,533

Age 55–64

9,787,669

10,399,398

11,622,856

9,787,669

12,234,586

19,575,337

Age 65+

1,231,393

2,052,322

1,231,393

1,026,161

1,026,161

1,847,090

103,685,447

159,007,014

143,877,999

122,589,270

154,450,924

170,082,464

0

1,584,637

0

1,584,637

1,584,637

3,169,274

Age 19–24

16,451,634

37,016,177

34,959,723

22,620,997

28,790,360

47,298,449

Age 25–34

126,006,176

145,227,457

190,077,112

145,227,457

126,006,176

160,177,342

Age 35–44

87,521,539

121,040,426

156,421,474

141,524,191

143,386,351

201,113,324

Age 45–54

56,313,585

87,744,424

89,054,042

70,719,386

82,505,951

107,388,698

Age 55–64

17,923,664

20,910,941

20,910,941

26,138,677

26,138,677

42,568,702

486,929

486,929

2,921,571

1,947,714

1,947,714

2,434,643

304,703,527

414,010,991

494,344,864

409,763,059

410,359,865

564,150,431

1,396,479

2,981,116

2,792,957

4,377,594

2,981,116

4,565,753

Total
Male
Age 0–18

Age 65+
Total
Overall
Age 0–18
Age 19–24

25,363,069

56,621,335

42,088,871

29,750,145

37,701,795

57,992,171

Age 25–34

155,903,208

196,228,277

248,112,528

183,917,734

184,041,592

200,626,268

Age 35–44

113,519,420

170,147,535

183,863,682

176,188,032

186,716,153

264,663,700

Age 45–54

82,777,143

113,190,153

124,678,062

99,218,603

112,022,996

139,959,231

Age 55–64

27,711,333

31,310,339

32,533,798

35,926,345

38,373,262

62,144,039

Age 65+
Total

1,718,322

2,539,251

4,152,965

2,973,875

2,973,875

4,281,733

408,388,974

573,018,005

638,222,863

532,352,329

564,810,789

734,232,894

Note: Lifetime lost productivity includes both of market and nonmarket activities. Productivity data from Grosse et al. (2019) are based on a 3
percent discount rate and 0.5 percent growth rate. Lower and upper bounds of the estimates presented in this table are available upon request.
The lower bound estimates are based on a 7 percent discount rate and 0.5 percent growth rate. The upper bound estimates are based on a 3
percent discount rate and 1 percent growth rate.
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The difference in median household income comes from the
US Census Bureau: https://www.census.gov/quickfacts/fact
/table/US,ME/INC110219.

Future work should also track drug-related morbidity and
mortality, as well as the economic impact, in a comparable
way across time. This is necessary to monitor the evolution
of the drug epidemic in Maine and to evaluate policies
and programs that are intended to address it.
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To calculate the years of potential life lost for each sex and
age group, we multiplied the number of deaths by the corresponding average life expectancy, weighted by the age distribution of the population. Information about life expectancy
comes from the 2017 Actuarial Life Table: https://www.ssa
.gov/OACT/STATS/table4c6.html.

NOTES
1

2

Drug overdose numbers are from the following Centers for
Disease Control and Prevention websites: https://www.cdc
.gov/opioids/basics/epidemic.html and https://www.cdc
.gov/nchs/pressroom/sosmap/drug_poisoning_mortality
/drug_poisoning.htm.
Population estimates used throughout this article come
from the following US Census Bureau table:
“Annual Estimates of the Resident Population for the
United States, Regions, States, the District of Columbia, and
Puerto Rico: April 1, 2010 to July 1, 2019; April 1, 2020; and
July 1, 2020 (NST-EST2020).” https://www.census
.gov/programs-surveys/popest/technical-documentation
/research/evaluation-estimates/2020-evaluation
-estimates/2010s-state-total.html.

3

This information comes from the Canadian Centre for
Occupational Health and Safety: https://www.ccohs.ca
/oshanswers/psychosocial/substance.html.

4

We calculate sex-specific prevalence of IDUD as follows:
Female prevalence of IDUD = [(Number of IDUD
cases * Proportion of cases that are female)/Female
population] * 100
Male prevalence of IDUD = [(Number of IDUD
cases * Proportion of cases that are male)/Male
population] * 100

5

7

Grosse et al. (2019) provide data on lifetime productivity per
person by sex and age. We use the sex-specific average
for each age group, weighted by the age distribution of the
population.
Discount rates are used to convert future economic value
into present terms. For example, a discount rate of 3 percent
per year implies that $1.03 a year from now equals $1.00
today.
To calculate lifetime lost productivity for each sex and age
group, we multiplied lifetime productivity per person by the
number of deaths.

8

The 95 percent confidence intervals overlap for females
and males in all years except 2017–2018. They also overlap
across time for females and males, respectively. Based on
this information, we cannot infer whether differences are
statistically significant, although it remains a possibility
(Austin and Hux 2002). SAMHSA only reports means and
confidence intervals.

9

Recall that annual lost productivity is a function of the
number of IDUD cases (Endnote 5). Thus, the 95 percent
confidence intervals on annual lost productivity merely
reflect those reported in the SAMHSA prevalence data.
Again, the 95 percent confidence intervals overlap for
females and males in all years, and across time. It cannot
be inferred whether differences are statistically significant,
although it remains a possibility (Austin and Hux 2002).

Prevalence of IDUD is given for individuals aged 12–17,
18–25 and 26+. However, productivity data from Grosse et al.
(2019) are given for those aged 15–24, 25–34, 35–44, 45–54,
55–64, 65–74 and 75–99. Thus, when studying individuals
aged 12–17 and 18–25, we use the productivity of those
aged 15–24. Likewise, when studying individuals aged 26+,
we use the average productivity of those aged 25–34, 35–44,
45–54, 55–64, 65–74, and 75–99, weighted by the age distribution of the population.
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